As alluded to in the introduction, phase II evaluation of trebananib (AMG386, a bispecific peptibody against Ang2 and Ang1) in the advanced metastatic setting of HER2− breast cancer showed no PFS benefit by adding trebananib to paclitaxel chemotherapy, with or without bevacizumab25. Here, ERBB2 is linked to breast carcinoma.